Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Problems in evaluating new antipsychotic drugs]

W W Fleischhacker1

  • 1Abteilung für Biologische Psychiatrie, Universitätsklinik für Psychiatrie, Innsbruck. wolfgang.fleischhacker@uibk.ac.at

Wiener Medizinische Wochenschrift (1946)
|September 25, 1998
PubMed
Summary

Novel antipsychotics offer expanded treatment options for schizophrenia. However, translating clinical trial success to real-world practice requires careful patient selection and critical risk-benefit evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.

Acta psychiatrica Scandinavica·2018
Same author

Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study.

Acta psychiatrica Scandinavica·2017
Same author

Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder.

Psychological medicine·2016
Same author

Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self-esteem.

Acta psychiatrica Scandinavica·2016
Same author

Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

European psychiatry : the journal of the Association of European Psychiatrists·2015
Same author

Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST).

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2015

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Trials

Context:

  • The last decade has seen the introduction of numerous novel antipsychotics into clinical practice.
  • These include medications such as olanzapine, quetiapine, risperidone, sertindole, zotepine, and ziprasidone.
  • Bridging the gap between clinical trial findings and daily psychiatric practice presents challenges.

Purpose:

  • To discuss methodological considerations in novel antipsychotic clinical trials, focusing on patient selection and trial design.
  • To provide an overview of current knowledge regarding novel antipsychotics.
  • To highlight the need for critical risk-benefit assessment and adaptation of treatment approaches.

Summary:

  • Novel antipsychotics have broadened therapeutic options for schizophrenia patients.
  • Translating clinical trial results into clinical practice is complex, necessitating attention to patient selection and trial methodology.
  • A critical evaluation of the risk-benefit ratio is essential for effective integration.

Impact:

  • These agents expand the therapeutic arsenal for schizophrenia management.
  • Successful integration requires adapting traditional treatment paradigms.
  • This facilitates the incorporation of novel antipsychotics into modern, integrative schizophrenia treatment strategies.

Related Experiment Videos